



GREATER COPENHAGEN
HEALTH • SCIENCE • PARTNERS

GREATER COPENHAGEN HEALTH SCIENCE PARTNERS RESEARCH & INNOVATION CONFERENCE 2025

EXCELLENT INNOVATION REQUIRES EXCELLENT RESEARCH

27 Clinical Academic Groups facilitate the transformation of patient care today and in the future — contributing to Denmark's future Health and Life Science Innovation Ecosystem

5th of December 2025
Rigshospitalet, Copenhagen



Region
Hovedstaden



UNIVERSITY OF
COPENHAGEN





Welcome to Greater Copenhagen Health Science Partners Research & Innovation Conference 2025 – Excellent Innovation requires Excellent Research

This booklet introduces you to the **27 Clinical Academic Groups (CAGs)** - the core engine of Greater Copenhagen Health Science Partners translational research community.

Each CAG brings together researchers and clinicians across our four partner organisations and beyond, forming a unique platform where scientific excellence, clinical insight, and innovation capacity come together to create real impact for real patients. Across the CAGs, more than **600 researchers** collaborate to facilitate that breakthroughs in science are translated into improved patient care through:

- new clinical guidelines
- advanced diagnostics
- novel treatments
- commercialisation of new inventions

At this year's conference, we place the outstanding translational research conducted within the CAGs at the centre of discussions about the wider Danish Health and Life Science Innovation Ecosystem,

We warmly invite you to explore the posters in this booklet which only showcase a fraction of the remarkable impact the CAGs are already having. Want to know more? Please, reach out!

We are always interested in discussing how we can support excellent research and innovation for better patientcare.

Thank you for your participation, your curiosity, and your contribution to shaping a stronger, more innovative health care system.



Ruth Frikke-Schmidt
Professor & Director
Greater Copenhagen Health Science Partners



Trine Middelbo
Sr. Executive Adviser
Greater Copenhagen Health Science Partners



GCHSP CLINICAL ACADEMIC GROUPS

CAG ALLERGY	Allergy
CAG IMPACT	Physical Activity and Sport in Clinical Medicine
CAG CARDIOLOGY	Precision Diagnostics in Cardiology
CAG HEMATOLOGY	Translational Hematology
CAG CHILD	Host Infections Laboratory Research Drugs
CAG ROAD	Research in OsteoArthritis Denmark
CAG MICROBIOME	Modulating the Infant Microbiome for Disease Prevention
CAG POS	Personalised Oncological Surgery
CAG LOGINFLAM	Systemic Low-Grade Inflammation
CAG SCIN	Skin Cancer Innovation Clinical Academic Group
CAG ACUTE	Prognostication of Acute Recovery Capacity – in an Aging Population
CAG ZIRI	The Zealand Inflammation Research Initiative
CAG ENDO	Center for Endotheliomics
CAG IGCS	Imaging-Guided Cancer Surgery
CAG BACINFECT	Novel strategies to diagnose and treat bacterial infections
CAG SURF	Regenerative Medicine for Urogenital Surgery and Fertility
CAG BAT	Brain and Technology
CAG SHIFT	Sustainable Health Improvements Following Obesity Treatment
CAG AGING	Fighting Frailty in Aging: Biological, Clinical and Social Aspects
CAG PSYCH	Precision Psychiatry
CAG CBIO	Clinical Bioinformatics
CAG WHIP	Women's Health in a Life Course Perspective
CAG DIGITAL	Digital Phenotyping for Home-based Treatment and Care
CAG ATMP	Accelerating Clinical Integration of Cell and Gene Therapies
CAG HOME	Home
CAG VAX	Translational Vaccine Research in High-Risk Adults
CAG PRECISE-IBD	Precision Medicine and Prognostic Stratification in Inflammatory Bowel Disease



CAG ALLERGY

CAG ALLERGY addresses the growing challenge of allergic diseases - including eczema, asthma, hay fever, food and drug allergies - by pioneering translational research in early detection, individualised treatments, and coherent care pathways across sectors.

“Personalised allergy care means fewer symptoms, fewer flare-ups, and a better quality of life. CAG ALLERGY is connecting clinicians with basic researchers, immunologists and engineers. This collaboration leads to better care, diagnosis, and treatment for patients with allergic diseases”.

- CAG Chair, Jeanne Duus Johansen, and CAG Vice-Chair, Charlotte Menné Bonefeld.

IMPACT ON PATIENT CARE

With improved early-detection tools, **patients spend less time waiting** and more time on effective treatment.

Coordinated pathways between primary care, specialists and research mean **fewer mis-referrals and more consistent, patient-centered care**.

IMPACT ON SOCIETY

Reduce hospital visits, emergency admissions and long-term complications from allergies.

By removing mis-diagnoses and unnecessary treatments, **resources are used more efficiently**.

Training the next generation of clinicians and researchers and **fostering collaboration across sectors**.

Does this sound interesting?
Please reach out – we are doing
so much more!



Jeanne Duus Johansen
Professor
National Allergy Research
Centre, Herlev and
Gentofte Hospital
CAG Chair



Charlotte Menné Bonefeld
Professor
Department of Immunology
and Microbiology (ISIM),
University of Copenhagen
CAG Vice-Chair



CAG IMPACT

CAG IMPACT drives translational research at the intersection of physical activity, sport, and clinical medicine, linking basic scientists and clinicians to integrate exercise and movement into prevention, treatment and rehabilitation of diseases and injuries.

“Exercise is medicine. Across diagnoses, one thing is clear: patients who move, recover better. CAG IMPACT brings the science, the tools and the clinical pathways together so physical activity becomes a natural part of prevention and treatment - not an afterthought”.

- CAG Chair, Michael Kjær, and CAG Vice-Chair, Flemming Dela.

IMPACT ON PATIENT CARE

Improves quality of life for the individual patient.

Faster rehabilitation and fewer complications after injury or illness.

Interventions are **adapted to the individual's condition, capacity and goal** — making physical activity safe, effective and relevant.

IMPACT ON SOCIETY

Lowers hospital readmissions, length of stay and long-term disability.

Lifestyle-driven illness is better managed and **fewer people becomes seriously ill**.

Promotes a new standard where “exercise as medicine” is built into care pathways and academic curricula.

Does this sound interesting?
Please reach out – we are doing
so much more!



Michael Kjær
Professor,
Bispebjerg and Frederiksberg
Hospital, The Capital Region
of Denmark
CAG Chair



Flemming Dela
Professor
Department of Biomedical
Sciences, University of
Copenhagen
CAG Vice-Chair



CAG ACUTE

CAG ACUTE works to improve the care of aging patients. By understanding who is likely to recover quickly and who needs extra support, we can give each patient the right treatment at the right time - and help more aging people regain their independence after hospitalisation.

“Aging patients admitted with acute illness are rarely a uniform group - their biology, comorbidities, medications and recovery capacity vary enormously. By using biomarker panels, organ-dysfunction profiling and advanced modelling, CAG ACUTE can stratify risk better, personalise treatment pathways and give older people a genuine chance at full recovery”.

- CAG Chair, Ove Andersen and CAG Vice-Chair, Lene Juel Rasmussen.

IMPACT ON PATIENT CARE

Tailored acute care to each patient **reduces complications**, supports **faster recovery**, and **improves quality of life**.

Lowers the risk of readmission and ensures sustained recovery at home due to safer transition plans.

IMPACT ON SOCIETY

Fewer readmissions, shorter admissions and **less reliance on long-term institutional care**.

System capacity is increased as 70 % of acute admissions involve older adults.

Does this sound interesting?
Please reach out – we are doing
so much more!



Ove Andersen
Professor, Chief
Physician Amager and
Hvidovre Hospital
CAG Chair



Lene Juel Rasmussen
Professor
Department of Cellular and Molecular
Medicine
University of Copenhagen
CAG Vice-Chair



CAG CARDIOLOGY

CAG CARDIOLOGY aims to move cardiac care from “one-size-fits-all” to precision diagnostics. Translating new genetic, molecular and imaging insights into clinical practice, the CAG works to identify the right diagnosis, the right mechanism — and ultimately the right treatment — for every cardiac patient.

“We treat hundreds of thousands of Danish cardiology patients, yet our diagnostic tools are still too unspecific. With CAG CARDIOLOGY we finally bring genetics, molecular profiling and advanced imaging into daily practice — so every patient gets a diagnosis that truly reflects their disease”.

- CAG Chair, Henning Bundgaard and CAG Vice-Chair, Søren Brunak.

IMPACT ON PATIENT CARE

Precise molecular and genetic understanding of each patient’s cardiac disease leads to **more accurate diagnoses**.

Tailored therapy rather than generic protocols enables **better treatment decisions**.

Precision care **reduces complications, long-term disability and mortality**.

IMPACT ON SOCIETY

Fewer treatment failures and complications **ease pressure on emergency care and cardiology departments**.

Accelerates translation of fast-growing genetic and molecular discoveries into real-world benefit.

Earlier, more accurate diagnostics help **prevent the high costs associated with late-stage cardiac disease**.

Does this sound interesting?
Please reach out – we are doing
so much more!



Henning Bundgaard
Professor
Department of Clinical
Medicine, The Heart
Center, Rigshospitalet, The
Capital Region of Denmark
CAG Chair



Søren Brunak
Professor
Novo Nordisk Foundation
Center for Protein
Research, University of
Copenhagen
CAG Vice-Chair



CAG CHILD

CAG CHILD marks a shift from one-size-fits-all treatment to truly personalised medicine - allowing children to receive safe, effective antibiotics therapy at home.

“For years, paediatric care relied on standard protocols. CAG CHILD is redefining paediatric care by using biology, data and clinical insight to tailor treatment for each child - reducing overtreatment, complications and unnecessary hospital days. That’s how we improve outcomes and strengthen families”.

- CAG Chair, Ulrikka Nygaard and CAG Vice-Chair, Søren Buus.

IMPACT ON PATIENT CARE

Children **recover faster and feel safer** when treated in their own home environment.

Families experience **less disruption, stress, and separation** during treatment.

Care becomes **more personalised** - tailored to each child’s recovery rather than a standard protocol.

IMPACT ON SOCIETY

Reduced hospital admissions **release healthcare resources** and lowers cost.

More precise antibiotic use helps **fight antibiotic resistance**.

Strengthens trust in healthcare innovation and promotes a shift towards patient-centered, home-based care.

Does this sound interesting?
Please reach out – we are doing
so much more!



Ulrikka Nygaard
Professor
Paediatric Infectious
Diseases, Rigshospitalet
CAG Chair



Søren Buus
Professor
Department of
Immunology and
Microbiology, University
of Copenhagen
CAG Vice-Chair

CAG ROAD

CAG ROAD improves quality of life for patients with musculoskeletal disease resulting in reduced societal cost.

“We’ve never been more optimistic about our ability to reduce pain and improve function for patients with musculoskeletal disease. Thanks to big data, new technologies, and true cross-disciplinary collaborations, we’re now developing both surgical and non-surgical treatments that are far less invasive - and far more effective than ever before”.

- CAG Chair, Anders Troelsen and CAG Vice-Chair, Stine Jacobsen.

IMPACT ON PATIENT CARE

Increased knowledge on non-surgical treatment for osteoarthritis means **fewer complications**.

Optimised surgical treatment has resulted in **better function and quality of life**.

IMPACT ON SOCIETY

Excellent translational research collaboration **prevents osteoarthritis**, keeping thousands of people moving.

Improved function allows more people with musculoskeletal disease to **remain as active members of the workforce**.

Does this sound interesting?
Please reach out – we are doing
so much more!



Anders Troelsen
Professor
Department of Orthopaedic
Surgery, Amager and
Hvidovre Hospital
CAG Chair



Stine Jacobsen
Professor
Department of Veterinary
Clinical Science,
University of Copenhagen
CAG Vice-Chair



CAG MICROBIOME

CAG MICROBIOME identifies the microbial and immune pathways that allow true disease prevention. The vision is that early-life microbiomes shape lifelong health.

“By tracking infants from the very start and understanding how microbial patterns set the stage for asthma and inflammation, we now have the chance to intervene early—shaping the microbiome before diseases takes hold and truly preventing illnesses. This approach holds real potential to reduce asthma cases among the 250.000–300.000 affected Danish adults and the 7–10% of school-aged children living with the disease”.

– CAG Chair, Klaus Bønnelykke, and CAG Vice-Chair, Søren Johannes Sørensen.

IMPACT ON PATIENT CARE

Healthier start in life, **fewer diseases and lowers risk of asthma** and chronic inflammatory disorders.

Tailored interventions in early life rather than one-size-fits-all.

Strengthening the infant microbiome may help build a more resilient immune system, **protecting children long before symptoms appear.**

Does this sound interesting?
Please reach out – we are doing
so much more!

IMPACT ON SOCIETY

Long-term savings for families and health care systems, through prevention rather than treatment.

Cross-sector collaboration creates a real opportunity to shift healthcare **from managing disease to preventing it altogether.**

A cost-effective alternative to expensive treatment of established disease.



Klaus Bønnelykke
Professor
Paediatrics, COPSAC
Herlev and Gentofte
Hospital
CAG Chair



Søren Johannes Sørensen
Professor
Department of Biology,
University of Copenhagen
CAG Vice-Chair



CAG POS

CAG POS aims to reduce morbidity and mortality for patients with colon and rectal cancer by integrating basic science, big-data analytics, and clinical research into truly personalised perioperative care.

“For too long, colorectal cancer surgery has been guided by standard pathways ignoring the individual biology of each patient. With CAG POS, we combine clinical data, biomarkers and mechanistic research to tailor perioperative treatment, which may lead to fewer complications, fewer relapses and improved patient survival”.

- CAG Chair, Ismail Gögenur and CAG Vice-Chair, Ali Salanti.

IMPACT ON PATIENT CARE

Personalised perioperative plans reduce unnecessary interventions and **improve safety**.

Better risk prediction lowers the risk of postoperative complications and helps patients **recover faster**.

Precision approaches may **reduce the risk of cancer relapse** after surgery.

IMPACT ON SOCIETY

Preventing complications means **more patients return to work and maintain independence**.

Avoiding postoperative complications and relapse **significantly decreases hospitalisation and lower costs**.

A new model for surgical precision medicine **strengthens Denmark's leadership** in integrating big data, lab science and clinical care.

Does this sound interesting?
Please reach out – we are doing
so much more!



Ismail Gögenur
Professor
Director of Center for
Surgical Science
Zealand University Hospital
CAG Chair



Ali Salanti
Professor
Department of Immunology and
Microbiology, University of
Copenhagen
CAG Vice-Chair



CAG LOGINFLAM

CAG LOGINFLAM becomes an internationally recognised center for research into low-grade inflammation (LGI), delivering high-quality science, education and innovation to reduce the patient and societal burden of LGI-related diseases.

“CAG LOGINFLAM bridges the gap from discovery to clinical action. We have the ability to move discoveries about low-grade inflammation directly from the laboratory into clinical care. By uniting basic science, epidemiology and frontline medicine, we aim to create new tools that fundamentally change how patients are diagnosed, treated and supported”.

- CAG Chair, Peter Riis Hansen and CAG Vice-Chair, Palle Holmstrup.

IMPACT ON PATIENT CARE

Tailored evaluation of inflammatory load and associated disease risk enables **earlier intervention**.

By targeting underlying inflammation, patients experience **fewer complications, comorbidities and residual risk of comorbidities**.

With LGI addressed early and effectively, patients achieve **higher functional health and quality of life**.

IMPACT ON SOCIETY

Lower healthcare cost and burden.

LOGINFLAM's cross-disciplinary platform **accelerates translation of inflammation science into clinical practice**.

Does this sound interesting?
Please reach out – we are doing
so much more!



Peter Riis Hansen
Professor
Department of Cardiology,
Herlev and Gentofte Hospital
CAG Chair



Palle Holmstrup
Professor
Department of
Odontology,
University of Copenhagen
CAG Vice-Chair



CAG SCIN

CAG SCIN aims to reduce the growing burden of skin cancer. By bringing dermatology, oncology, surgery and transplantation together across regions, the CAG works to ensure equal, high-quality care for all patients.

“Skin cancer is the most common cancer - and for many people, it’s entirely preventable. With CAG SCIN, we aim to identify those at highest risk of developing skin cancer, enable earlier diagnosis, and develop better and more tolerable treatments. Through this initiative, CAG SCIN seeks to mitigate disease burden and elevate the standard of care”.

- CAG Chair, Merete Hædersdal and CAG Vice-Chair, Mads Nielsen.

IMPACT ON PATIENT CARE

Patients get **earlier and more precise diagnosis** followed by personalised treatment based on their individual risk.

Clearer guidance and prevention **help people reduce sun exposure risks** and prevent new tumours.

All patients **receive the same high standard of treatment** across regions.

IMPACT ON SOCIETY


Fewer advanced cases and recurrent tumors **ease the burden on the healthcare system**.

Better prevention leads to fewer new cases in the population, **improving overall public health**.

Does this sound interesting?
Please reach out – we are doing
so much more!



Merete Hædersdal
Professor
Department of Dermatology,
Bispebjerg and Frederiksberg
Hospital
CAG Chair



Mads Nielsen
Professor
Department of
Computer Science,
University of
Copenhagen
CAG Vice-Chair



CAG ACUTE

CAG ACUTE works to improve the care of aging patients. By understanding who is likely to recover quickly and who needs extra support, we can give each patient the right treatment at the right time - and help more aging people regain their independence after hospitalisation.

“Aging patients admitted with acute illness are rarely a uniform group - their biology, comorbidities, medications and recovery capacity vary enormously. By using biomarker panels, organ-dysfunction profiling and advanced modelling, CAG ACUTE can stratify risk better, personalise treatment pathways and give older people a genuine chance at full recovery”.

- CAG Chair, Ove Andersen and CAG Vice-Chair, Lene Juel Rasmussen.

IMPACT ON PATIENT CARE

Tailored acute care to each patient **reduces complications**, supports **faster recovery**, and **improves quality of life**.

Lowers the risk of readmission and ensures sustained recovery at home due to safer transition plans.

IMPACT ON SOCIETY

Fewer readmissions, shorter admissions and **less reliance on long-term institutional care**.

System capacity is increased as 70 % of acute admissions involve older adults.

Does this sound interesting?
Please reach out – we are doing
so much more!



Ove Andersen
Professor, Chief
Physician Amager and
Hvidovre Hospital
CAG Chair



Lene Juel Rasmussen
Professor
Department of Cellular and
Molecular Medicine
University of Copenhagen
CAG Vice-Chair



CAG ZIRI

CAG ZIRI strengthens the link between basic discovery and clinical care to detect Myeloproliferative Neoplasms in blood cancer (MPN) earlier and improve outcomes for patients with MPN blood cancers and their complications.

“What appears as a rare blood cancer is, in reality, a hidden population with early genetic changes. Myeloproliferative Neoplasms in blood cancer may appear as rare but many people carry the genetic changes long before diagnosis. At ZIRI, we bring together mutation screening, clinical research and big data modelling so that early-stage blood cancer patients are identified and treated before irreversible damage sets in”.

- CAG Chair, Hans Carl Hasselbalch and CAG Vice-Chair, Bulat Ibragimov.

IMPACT ON PATIENT CARE

Earlier diagnosis by identifying people with MPN mutations prior to a fully developed disease.

Reduced complication risk e.g. blood clots, organ damage and secondary cancers.

Less disease progression and fewer comorbidities **improves overall quality of life.**

Does this sound interesting?
Please reach out – we are doing
so much more!

IMPACT ON SOCIETY

Preventing complications and late-stage disease **reduce hospital admissions and the chronic care burden.**

CAG collaboration drives innovation, training and **advances translational research** in inflammation and blood science.



Hans Carl Hasselbalch
Professor, dr. med.,
Department of
Hematology, Zealand
University Hospital,
CAG Chair



Bulat Ibragimov
Associate Professor
Department of Computer
Science, DIKU,
University of Copenhagen
CAG Vice-Chair



CAG ENDO

CAG ENDO transforms critical and intensive care through precision medicine — using endothelial biology, biomarkers, and computational models to predict, prevent, and personalise treatment for life-threatening organ failure.

“We are rethinking management of trauma and intensive care patients, because patients with identical injuries can have completely different risk of dying. By using computer models of the endothelial response to the injury and biomarker profiles, at the individual level, we can now identify those high-risk patients early and tailor treatment to their specific needs - giving each patient the best possible chance of survival”.

- CAG Chair, Pär Ingemar Johansson and CAG Vice-Chair, Bernhard Palsson.

IMPACT ON PATIENT CARE

High-risk trauma and ICU patients are identified earlier, **enabling life-saving interventions**.

Personalised care reduces the risk of organ failure and **improves survival**.

Treatments are guided by **each patient's biology**, not assumptions about "the typical patient."

Does this sound interesting?
Please reach out – we are doing
so much more!

IMPACT ON SOCIETY

Shorter stays in the ICU **reduces hospital cost**.

Biological insights drive the shift towards precision medicine.

Danish research has introduced the **endothelium as target organ**.



Pär Ingemar Johansson
Professor
Department of Clinical
Immunology, Rigshospitalet
CAG Chair



Bernhard Palsson
Professor, Scientific Director
Novo Nordisk Foundation
Center for Biosustainability, DTU
CAG Vice-Chair



CAG IGCS

CAG IGCS aims to dramatically improve surgical outcomes for cancer patients by using advanced imaging and navigation technology to ensure complete tumor removal - leading to longer survival and better quality of life.

“The hardest part of cancer surgery is knowing exactly where the tumour ends. With optical imaging and 3D navigation, we can finally see what was invisible before. Our CAG brings this technology from the lab into the operating room - giving patients a better chance of cure and a faster return to life”.

- CAG Chair, Christian von Buchwald and CAG Vice-Chair, Andreas Kjær.

IMPACT ON PATIENT CARE

More precise surgery reduces the risk that small cancer fragments are left behind and **fewer relapses**.

Less need for harsh follow-up treatment.

Better recovery, reduction of complications and quality of life.

Does this sound interesting?
Please reach out – we are doing
so much more!

IMPACT ON SOCIETY

Fewer relapses and fewer intensive follow-up treatments **reduce healthcare costs**.

New imaging technology **improve precision, safety and resource use** in complex cancer surgery.

Strong commercial and international scaling potential, as optical imaging and 3D-navigation technologies can be applied across multiple cancer types and surgical procedures.



Christian von Buchwald
Professor, DMSc,
Head & Neck Surgery and
Audiology, Rigshospitalet
CAG Chair



Andreas Kjær
Professor
Department of Biomedical
Sciences Cluster for Molecular
Imaging, University of
Copenhagen
CAG Vice-Chair



CAG BACINFECT

CAG BACINFECT improves treatment outcome among patients with infectious diseases through better diagnostics and development of new therapeutic strategies.

“Bacterial infections are becoming one of our greatest threats — not just because of resistance, but because we’ve fallen behind in diagnosing and treating them quickly. At BACINFECT we bridge lab and clinic: we find new infection markers, study why treatment fails and search for solutions that save lives”.

- CAG Chair, Helle Krogh Johansen and CAG Vice-Chair, Søren Molin.

IMPACT ON PATIENT CARE

Earlier, accurate diagnosis.

Better, tailored therapy that is more effective and less harmful.

Improved recovery reducing suffering and improving quality of life.

IMPACT ON SOCIETY

Reduced antibiotic resistance in society.

Increased knowledge about bacterial infection processes.

Stronger research-to-clinical protocol implementation.

Attractive for commercial partners and health systems globally as scalable diagnostics and algorithms address a universal clinical challenge.

Does this sound interesting?
Please reach out – we are doing
so much more!



Helle Krogh Johansen
Professor, Chief Physician,
Department of Clinical
Microbiology,
Rigshospitalet
CAG Chair



Søren Molin
Professor
DTU Biosustain, Technical
University of Denmark
CAG Vice-Chair



CAG SURF

CAG SURF accelerates translation of regenerative medicine research into clinical practice, to heal or replace damaged urogenital organs and restore fertility-improving outcomes and quality of life for patients with rare urogenital disorders.

“What makes CAG SURF unique is our ability to take laboratory innovations - stem-cell models, bioprinted structures, regenerative scaffolds - and move them directly into clinical pathways. This is where basic science truly changes patient outcomes”.

- CAG Chair, Magdalena Fossum and CAG Vice-Chair, Johan Ulrik Lind.

IMPACT ON PATIENT CARE

Faster access to cutting-edge regenerative treatments for urogenital conditions.

Reduced need for repeated surgeries and better preservation of organ function and fertility.

Improved autonomy and psychological well-being for patients facing complex reconstructive challenges.

IMPACT ON SOCIETY

Lower long-term costs associated with chronic urogenital disorders and repeated care.

Strengthened capacity for translational surgical innovation and cross-disciplinary training.

High commercial value and scalability across multiple urogenital conditions paving the way for new treatment paradigms.

Does this sound interesting?
Please reach out – we are doing
so much more!



Magdalena Fossum
Professor, Clinical Consultant,
Department of Paediatric
Surgery, Rigshospitalet
CAG Chair



Johan Ulrik Lind
Associate Professor,
Department of Health
Technology,
DTU
CAG Vice-Chair



CAG BAT

CAG BAT works to improve diagnosis, monitoring and treatment of neurological disorders by using digital technologies - from wearables and implantables to AI-driven analytics — bringing patient-centered data into real-world care.

“Neurological diseases often progress silently. With CAG BAT, we bring together sensors, data science and clinical insight to detect changes long before symptoms escalate - transforming how we diagnose, monitor and support patients. In other words, CAG BAT makes the invisible visible - turning everyday technology into tools that improve neurological health and patient outcomes”.

– CAG Chair, Martin Ballegaard and CAG Vice-Chair, Paul Michael Petersen.

IMPACT ON PATIENT CARE

Faster and more accurate care.

Tailored treatment plans that **adapt to each patient’s daily life and needs.**

Fewer hidden relapses thanks to continuous care outside the hospital environment.

IMPACT ON SOCIETY

Better management of neurological disorders **reduces hospitalisations, long-term care and societal costs.**

Strengthens Denmark’s capacity to handle the growing burden of neuro-disease in an aging population.

Strong pathways for commercialization in the fast-growing digital-health and neuro-tech sectors.

Does this sound interesting?
Please reach out – we are doing
so much more!



Martin Ballegaard
Associate Professor, Chief
Physician
Department of Neurology,
Zealand University Hospital
CAG Chair



Paul Michael Petersen
Professor,
Department of Electrical
and Photonics Engineering,
DTU
CAG Vice-Chair



CAG SHIFT

CAG SHIFT transforms the treatment of severe obesity and its complications - shifting it from a chronic condition with limited options to one where long-term improvements in physical and mental health are achievable and maintainable.

“In obesity care, the real challenge is not weight loss – it is sustaining health benefits over time. With CAG SHIFT, we integrate physiology, psychology and clinical practice to support long-term health improvements. We ensure that our SHIFT innovations are grounded in the individual's everyday life, making sustainable obesity care possible for more people”.

- CAG Chair, Signe S. Torekov and CAG Vice-Chair, Kristine N. Bojsen-Møller.

IMPACT ON PATIENT CARE

Reduction of lifelong medication for patients.

Tailored treatment to each person's needs, motivations and capacities.

IMPACT ON SOCIETY

Stronger capacity for sustainable care in obesity management that supports **healthier populations and reduce systemic risk.**

Reduced long-term healthcare burden from obesity-related diseases and complications.

Does this sound interesting?
Please reach out – we are doing
so much more!



Signe S. Torekov
Professor
Department of Biomedical
Sciences, University of
Copenhagen
CAG Chair



Kirstine N. Bojsen-Møller
Clinical Associate
Professor, Chief Physician
Amager and Hvidovre
Hospital
CAG Vice-Chair



CAG AGING

CAG AGING transforms how we understand and treat frailty in older people. By combining early detection, targeted training, digital tools, and coordinated care pathways, CAG AGING aims to prevent frailty rather than react to it.

“Fragility is not an inevitable part of aging. With CAG AGING we combine early detection, targeted interventions and cross-sector care to help older people stay stronger, recover faster and maintain independence for longer. We aim to enable personalised prevention and coordinated care that truly changes the trajectory of aging”.

- CAG Chair, Charlotte Suetta and CAG Vice-Chair, Jørn Wulff Helge.

IMPACT ON PATIENT CARE

Early detection and tailored training help **prevent frailty and loss of independence.**

Coordinated plans across hospital, community, and home ensure **the right help at the right time.**

Digital tools support **self-monitoring, motivation, and connection** to caregivers.

IMPACT ON SOCIETY

Preventive care **lowers the need for acute treatment,** admissions and long-term care.

More older adults **remain active, independent, and socially engaged.**

Collaboration across sectors drives innovation and **relieves system strain.**

Does this sound interesting?
Please reach out – we are doing
so much more!



Charlotte Suetta
Clinical Professor
Geriatrics, Bispebjerg and
Frederiksberg Hospital
CAG Chair



Jørn Wulff Helge
Professor
Department of Biomedical
Sciences, Exercise and Muscle,
University of Copenhagen
CAG Vice-Chair



CAG PSYCH

CAG PSYCH integrates data science, neuroscience and clinical psychiatry to improve diagnosis and treatment of psychiatric disorders. The aim is to identify biomarkers, stratify patients, and deliver more precise, individualised care that reduces illness and saves lives.

“Psychiatric care is entering a new era. Psychiatric care has till now relied on broad diagnostic categories and generic treatments. At CAG PSYCH we’re building pipelines - from big data, omics and imaging into real-world trials – matching treatment to the right patient at the right time”.

- CAG Chair, Michael Eriksen Benros and CAG Vice-Chair, Simon Rasmussen.

IMPACT ON PATIENT CARE

Earlier and more accurate diagnosis through biomarkers.

More effective, tailored interventions that **reduce trial-and-error in treatment and resulting in improved recovery.**

Enhanced **quality of life** as treatment is more precise and less invasive.

IMPACT ON SOCIETY

Reduced long-term disability and mortality linked to psychiatric disorders.

Optimised use of healthcare resources by focusing treatment and reducing ineffective care.

Strengthened research-clinical translation framework in mental health - positioning Denmark as a leader in precision psychiatry.

Does this sound interesting?
Please reach out – we are doing
so much more!



Michael Eriksen Benros
Professor, Chief Physician
Mental Health Services in
the Capital Region of
Denmark
CAG Chair



Simon Rasmussen
Professor
Faculty of Health and
Medical Sciences,
University of Copenhagen
CAG Vice-Chair

CAG CBIO

CAG CBIO strengthens clinical decision-making by bringing advanced bioinformatics directly to the clinic. By uniting algorithm developers, clinical bioinformaticians and clinicians, the CAG implements tools that transform massive data into fast and actionable guidance for patient care.

“Modern medicine generates billions of data points per patient - but they only truly matter when transformed into knowledge that clinicians can act on. CAG CBIO connects algorithm innovation with clinical implementation for patients to receive faster, more precise treatment based on their unique biology”.

– CAG Chair, Lars Rønn Olsen and CAG Vice-Chair, Frederik Otzen Bagger.

IMPACT ON PATIENT CARE

New algorithms **reduce the time from sample to clinical decision**, diagnoses and treatment adjustments.

Omics-based tools allow clinicians to **tailor treatments** based on each patient's genetic and molecular profile.

Early relapse prediction and treatment optimisation **improve survival and quality of life**.

IMPACT ON SOCIETY

Automated data analysis **reduces workload across hospital laboratories**.

Smarter use of data by turning massive genomic and molecular datasets into precision medicine across the health system.

A stronger innovation ecosystem builds a bridge between university research and hospital implementation, closing a critical skill and translation gap.

Does this sound interesting?
Please reach out – we are doing
so much more!



Lars Rønn Olsen
Professor
Department of Immunology
and Microbiology, University
of Copenhagen
CAG Chair



Frederik Otzen Bagger
Professor
Head of Bioinformatics
Rigshospitalet
CAG Vice-Chair



CAG WHIP

CAG WHIP leads a data-driven transformation in women's health by uncovering the biological mechanisms behind menstruation, pregnancy and menopause.

“Women's health has been under-researched for generations. CAG WHIP is about one thing: giving women evidence-based healthcare at every stage of life. With CAG WHIP, we are using multi-omics data, powerful AI data and real-world evidence to uncover the biological mechanisms behind menstruation, pregnancy and menopause and its impact on long-term health”.

- CAG Chair, Henriette Svarre Nielsen and CAG Vice-Chair, Majken Karoline Jensen.

IMPACT ON PATIENT CARE

New biomarkers and risk tools support **earlier detection and tailored treatment** for conditions like endometriosis, migraine and menopause-related symptoms.

Improved pathways and user experiences for birth-related care, miscarriage support and reproductive health consultations.

Evidence-based benchmarks of “normal” enable **more accurate clinical decisions**.

IMPACT ON SOCIETY

Better diagnostics, clearer guidelines and data-driven policies **strengthen equity across women's healthcare**.

Accelerates translation from research to practice and **raises the standard for women's health research and education** across Denmark.

Does this sound interesting?
Please reach out – we are doing
so much more!



Henriette Svarre Nielsen
Professor
Department of Obstetrics
and Gynaecology,
Amager and Hvidovre
Hospital
CAG Chair



Majken Karoline Jensen
Professor
Department of Public Health,
University of Copenhagen
CAG Vice-Chair



CAG DIGITAL

CAG DIGITAL advances home-based treatment by developing and implementing smart digital tools and algorithms that monitor, analyse and support patient care remotely. The goal is to shift treatment closer to home, improve patient outcomes and ease the burden on healthcare systems.

“Home-based care only succeeds when the technology truly works for patients. With CAG DIGITAL we bring clinicians, engineers, users and data scientists together to create tools that are safe, user-friendly and clinically meaningful”.

- CAG Chair, Jakob Bardram and CAG Vice-Chair, Thea Kølsen Fischer.

IMPACT ON PATIENT CARE

Care that fits life at home when reducing travel, stress and time away from daily routines.

Reliable sensors and smart analytics help **detect worsening symptoms sooner** and tailor treatment in real time.

User-friendly tools make it easier to manage chronic conditions **without adding complexity to patients' lives**.

IMPACT ON SOCIETY

Reduces admissions, clinic visits and demand for scarce healthcare staff.

Secure, transparent AI and improved data analysis **strengthen decision-making** across the system.

A dedicated test facility ensures new technologies are evaluated in realistic settings prior to scaling into practice - **accelerating innovation**.

Does this sound interesting?
Please reach out – we are doing
so much more!



Jakob Bardram
Professor
Department of Health
Technology, Technical
University of Denmark
CAG Chair



Thea Kølsen Fischer
Professor, Director
Department of Clinical
Research, Nordsjællands
Hospital
CAG Vice-Chair



CAG ATMP

CAG ATMP (Advanced Therapy Medicinal Product) accelerates the development and clinical use of advanced therapies - including cell therapy, gene therapy and regenerative medicine - to give patients faster and more equal access to future curative treatments.

“Denmark has world-class research in cell and gene therapy, but patients won’t fully benefit until we close the gap between innovation and clinic. By uniting researchers, clinicians, and educators, the CAG builds the infrastructure, skills and standards needed to move Advanced Therapy Medicinal Products safely and efficiently from the lab to real patient care. CAG ATMP builds the shared platforms, trials and competencies needed to make these treatments part of everyday care”.

- CAG Chair, Inge Marie Svane and CAG Vice-Chair, Sine Reker Hadrup.

IMPACT ON PATIENT CARE

Faster pathways for cell, gene and regenerative therapies give patients with severe or rare diseases **new options when conventional treatments fail.**


Standardised procedures and transparent clinical pathways reduce delays, uncertainty and risks creating **safer and more consistent care.**

IMPACT ON SOCIETY


Shared ATMP infrastructure and clinical trial platforms **accelerate research, industry collaboration and biomedical growth.**

Coordinated standards and well-trained staff **streamline approval, production and clinical use of advanced therapies.**

Does this sound interesting?
Please reach out – we are doing
so much more!



Inge Marie Svane
Professor, Director,
Department of Oncology,
Herlev and Gentofte
Hospital
CAG Chair



Sine Reker Hadrup
Professor,
Department of Health
Technology, Technical
University of Denmark
CAG Vice-Chair



CAG HOME

CAG HOME accelerates the transition towards Hospital-at-Home. Developing evidence-based digital technologies, redesigning workflows and integrating home-based diagnostics, treatment and monitoring, the CAG works to relieve system pressure and empower patients.

”Hospital-at-Home isn’t a nice-to-have - it’s essential. With an aging population and fewer healthcare workers, we must move safe, evidence-based treatment into patients’ homes. CAG HOME builds the technology, culture and clinical pathways to make that shift real”.

- CAG Chair, Christian Sylvest Meyhoff and CAG Vice-Chair, Boris Döder.

IMPACT ON PATIENT CARE

Increased care at home, **reducing the need for hospital admission.**

Digital tools give patients **more control, better insight and clearer communication** with clinicians.

Home-based care minimises **stress, travel, and time spent away from family and daily life.**

IMPACT ON SOCIETY

Shifting care from the hospital to the individual patients home **frees up staff, beds and resources.**

New workflows and cross-sector collaboration connect hospitals and primary care in a **more resilient and coherent digital ecosystem.**

Does this sound interesting?
Please reach out – we are doing
so much more!



Christian Sylvest Meyhoff
Professor, Head of Research
Department of
Anaesthesiology and Intensive
Care, Bispebjerg and
Frederiksberg Hospital
CAG Chair



Boris Döder
Associate Professor
Department of Computer Science,
Software, Data, People & Society,
University of Copenhagen
CAG Vice-Chair



CAG VAX

CAG VAX works to ensure that high-risk adults - including aging patients, those with advanced chronic disease, and immunosuppressed individuals - gain safe, equal and evidence-based access to vaccines.

“For too long, the people who need vaccines the most have been the least studied. With CAG VAX we open the door to high-risk adults - building trials, clinics and immunology insights that finally reflect their needs. By creating an inclusive research and clinical platform, the CAG advances our understanding of immune responses, improves vaccination strategies, and strengthens protection for the most vulnerable”.

- CAG Chair, Professor Zitta F. Barella Harboe and CAG Vice-Chair, Lea Klingenberg Barfod.

IMPACT ON PATIENT CARE

Better protection from severe infections with tailored vaccination strategies.

Safer and more reliable guidance for groups historically left out of trials.

IMPACT ON SOCIETY

Lower hospitalisations and system strain due to more vaccine coverage in vulnerable populations.

Evidence-based national policy strengthens vaccine recommendations and public-health decisions.

More equitable healthcare by closing knowledge gaps ensures that high-risk groups are no longer underserved in preventive care.

Does this sound interesting?
Please reach out – we are doing
so much more!



Zitta F. Barella Harboe
Clinical professor
Department of Respiratory
Medicine and Infectious
Diseases
Nordsjællands Hospital
CAG Chair



Lea Klingenberg Barfod
Professor
Department of
Immunology and
Microbiology,
University of Copenhagen
CAG Vice-Chair



CAG PRECISE-IBD

CAG PRECISE-IBD transforms care for patients with inflammatory bowel disease (IBD) by using detailed molecular and clinical profiling to stratify disease, personalise treatment and improve long-term outcomes.

“Inflammatory bowel disease (IBD) is more than a disease of the gut - it’s a complex mix of genetics, immune response, microbiome and environment. With PRECISE-IBD we bring multi-omics, clinical data and prognostic modelling together to tailor treatment for a specific patient and change what we expect from IBD care”.

- CAG Chair, Johan Burisch and CAG Vice-Chair, Torben Hansen.

IMPACT ON PATIENT CARE

Detailed molecular profiling **allows earlier identification of disease patterns.**

Faster tailored treatment plans due to easier identification of patient-specific disease trajectories.

Personalised care **reduces risk of relapse, complications and improves quality of life.**

IMPACT ON SOCIETY

More precise treatment means fewer ineffective therapies, **fewer complications and lower long-term costs.**

Stratification of patients enables better allocation of therapies and **avoids over-treatment.**

Strengthened research-clinical translation – building the bridge from large-scale biomarker discovery to improved patient care models.

Does this sound interesting?
Please reach out – we are doing
so much more!



Johan Burisch
Clinical Professor
Gastro Unit, Amager and
Hvidovre Hospital
CAG Chairs



Torben Hansen
Professor
Novo Nordisk Foundation
Center for Basic Metabolic
Research, University of
Copenhagen
CAG Vice-Chair

Learn more at www.gchsp.dk



GREATER COPENHAGEN
HEALTH • SCIENCE • PARTNERS



Region
Hovedstaden



UNIVERSITY OF
COPENHAGEN

